Daewoong Pharmaceutical Co Ltd 2023 SR
The report highlights Daewoong Pharmaceutical's inaugural ESG strategy, 'CARE for people and planet,' focusing on healthcare innovation and environmental stewardship. Key achievements in 2022 include the successful launch of new drugs Fexuclue and Envlo, and reaching record sales exceeding 1.2 trillion KRW. The company demonstrated environmental commitment by reducing energy and carbon intensity for three consecutive years and achieving ISO 14001 and 45001 certifications. Social highlights include achieving zero workplace accidents and being recognized as a 'Supreme Family-friendly Company.'
Company: Daewoong Pharmaceutical Co Ltd
Sector: Manufacturing
Country: South Korea
Year: 2023
Type: SR
Pages: 108
Daewoong Pharmaceutical Co Ltd
The report highlights Daewoong Pharmaceutical's inaugural ESG strategy, 'CARE for people and planet,' focusing on healthcare innovation and environmental stewardship. Key achievements in 2022 include the successful launch of new drugs Fexuclue and Envlo, and reaching record sales exceeding 1.2 trillion KRW. The company demonstrated environmental commitment by reducing energy and carbon intensity for three consecutive years and achieving ISO 14001 and 45001 certifications. Social highlights include achieving zero workplace accidents and being recognized as a 'Supreme Family-friendly Company.'
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Apr 1, 2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees